Introducing the Pipeline-to-Patient Productivity Index (P3i)
The P3i is the first benchmark to follow drug performance across the entire development and commercialization lifecycle. It is made possible by Norstella’s unique position across the pharma value chain. The index is designed to support capital allocation and portfolio decisions across biopharma. The report spans the top 25 publicly listed biopharmaceutical companies and provides […]
Working Backwards: Patient Access Strategy is Now Guiding R&D
Drawing from research from across the breadth of Norstella, this white paper lays out the argument for the increasing strategic influence of patient access. The pricing and reimbursement landscape in the US remains volatile as the various stakeholders react to new policies and the increasing complexity of new drug launches. This is creating the conditions […]
Innovation Trends from R&D to Market Access
2024 has been an incredibly busy year for Norstella as its constituent organizations – Citeline, Evaluate, MMIT, Panalgo, and the Dedham Group – have continued to support the biopharma ecosystem in bringing new therapies to patients. Throughout the course of the year, we have also shared our latest views on the issues that are most […]
Assessing AI Transformation in Pharma R&D: Current and Future Impact
Artificial intelligence (AI) has been one of the largest disruptors in drug development over the past few years, with the promise of innovation and greater efficiencies keeping the pharma industry heavily invested. There have been major advancements in AI-discovered molecules and AI-powered platforms for decentralized treatment, in addition to many more AI applications that have […]
The Current & Future Impact of AI on Pharmaceutical R&D
Artificial intelligence (AI) continues to disrupt existing paradigms in drug development, with early adopters experiencing both the benefits and challenges of this innovative technology. With that in mind, Norstella surveyed 125 senior decision-makers in the life sciences industry on their perceptions and expectations of AI to understand current AI adoption trends in addition to the […]
Obesity R&D in 2024 & Beyond: Key Considerations in an Increasingly Competitive Landscape
Norstella empowers stakeholders involved in obesity drug development to make informed decisions based on trusted industry data and expert insights. This infographic uses some of those data and insights to demonstrate the various complex factors that continue to impact obesity R&D, assess expectations for future development in this space, and emphasize how Norstella serves as […]
